Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 P592 | DOI: 10.1530/endoabs.56.P592

1Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain; 2Biocruces Research Institute, Bizcaia, Spain; 3Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; 4Department of Morphological Sciences of Santiago de Compostela, Santiago de Compostela, Spain.


Introduction: p53 is transcription factor widely known because of its antitumoral actions. New evidences suggest that p53 also play a key role in the regulation of metabolic homeostasis and specifically in the lipid metabolism.

Objective: We hypothesize that the chemical activation of p53 with low doses of doxorubicin could ameliorate the lipid metabolism in in vitro models of liver steatosis.

Methods: We treated with low concentrations of doxorubicin two human hepatic cell lines, HepG2 and THLE-2, exposed to oleic acid to induce lipid accumulation. Furthermore, we administered doxorubicin to HepG2 cells downregulating p53 with siRNAs.

Results: The doxorubicin treatment reduced the lipid accumulation in two human hepatic cell lines in a p53-dependent manner. The drug stimulated the lipid oxidation and inhibited the de novo lipogenesis at concentrations that did not affect the cell viability or apoptosis.

Conclusion: The activation of p53 with low doses of doxorubicin could provide a new strategy to reduce the lipid accumulation in the liver of patients with hepatic steatosis.

Acknowledgements: This work has been supported by the predoctoral fellowship from Ministerio de Educación, Cultura y Deporte, through the Plan Estatal de Investigación Científica y Técnica y de Innovación 2013–2016.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.